Cellular Technology Ltd （CTL）公司介绍

简要描述：国凯斯西储大学（CWRU）的病理学教授Paul V. Lehmann博士开发出新一代ELISPOT检测技术，继而创立CTL公司，致力于为用户提供Z精确的ELISPOT检测仪器和解决方案。

详细介绍

产品咨询

美国Cellular Technology Ltd （CTL）  www.elispot.cn  www.immunospot.com
　Cellular Technology Ltd （CTL）是世界和zui大的 ELISPOT 技术解决方案提供商。CTL 由 1996 年在美国 Ohio Case Western Reverse University 大学发明新一代 ELISPOT 分析方法的 Paul V. Lehmann 教授所创建。
CTL 是 ELISPOT 技术的世界*，*创立了当代新型 ELISPOT 方法，将 ELISPOT 技术提升到了精确科学的高度；*将图像分析引入到 ELISPOT中，制造出世界上*台商业 ELISPOT 分析仪。CTL 15年来一直从事细胞免疫学研究，专注于 ELISPOT 领域已经超过 10 年的历史。CTL 是美国 NIH 免疫耐受网*的 ELISPOT 分析实验室和分析仪提供商。CTL 提供 ELISPOT 分析仪硬件、软件和相关服务。是世界上*能提供全套 ELISPOT 服务，包括双色分析、质量控制和大规模 ELISPOT 协约服务在内的技术提供商。敬请，探讨 ELISPOT 技术如何为您的科研、临床和新药研制等领域提供有力的帮助。
Cellular Technology Ltd. was formed in 1998 by Dr. Paul V. Lehmann, a Professor at the Case Western Reserve University School of Medicine. 

Dr. Lehmann is a leader in the field of T cell immunology with over 20 high ranking publications dedicated to establishing the scientific basis of cytokine ELISPOT analysis.

Dr. Lehmann developed the original ImmunoSpot technology in order to conduct his own research more effectively. The ImmunoSpot platform is the most frequently referenced in the scientific literature in this field and is widely accepted to be the gold standard. Applications of ImmunoSpot technology include diagnosis and drug discovery for infectious diseases such as HIV and tuberculosis, better understanding and treatment of allergies and autoimmunity, the ability to predict rejection/acceptance responses in organ transplantation and significant improvements in vaccine development and monitoring including for various cancers where post treatment monitoring will be a key part of the therapy.

Dr. Lehmann pioneered the development of tools to accuray and reproducibly measure T cell responses. Dr. Lehmann and CTL designed and constructed the world’s very first ELISPOT reader under US Patent No: 6,410,252 （Methods for Measuring T Cell Cytokines, issued June 25, 2002）. The company has been at the forefront of this field ever since.

In 2001, CTL established a laboratory to provide assay services to companies and academic researchers involved in cellular immunology research, drug discovery and drug development. These services include immunogenicity testing, plate scanning and analysis, and ELISPOT assay training.

Within recent years, CTL has expanded its platform to include additional products and services for those in the scientific community. These include cryopreserved PBMC, serum-free media, plaque and colony counters, and expanded contract research services.

Headquartered in Cleveland, Ohio, CTL has expanded to include offices in China, Germany, and Japan.

 CTL has been recognized as the leader in basic science publications about （and clinical application of） ELISPOT assays, instrumentation, software, and reagent solutions. CTL is the only entity that specializes in developing ELISPOT instrumentation, assays, and their implementation in GLP compliant contract research. As such, CTL has been recognized by the Cancer Vaccine Consortium as the ELISPOT reference laboratory and has been awarded by the U.S. National Institutes of Health （NIH） a contract for the validation of the ELISPOT assay for clinical trials.

In recent years, CTL has expanded to include instrumentation for evaluating bioassays as well as reagent solutions including cryopreserved PBMC samples and serum-free media.

Because of its commitment to world-class quality and performance, CTL was awarded the 2005 “Excellence in Exporting” award by the State of Ohio’s Governor’s Office.

Today, CTL’s instrumentation and products are placed in over 30 countries, with over 350 institutes adopting the ImmunoSpot® platform for their immunological research needs.